Northera Survives Questions About Benefit Of Dizziness Endpoint At Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cardiovascular and Renal Drugs Advisory Committee Jan. 14 supported approval of the drug for symptomatic neurogenic orthostatic hypotension on a vote of 16-1.